1
ALL1
AbiologicsYear
1
ALL1
2024DEALS // DEV.
1
ALL1
DealsCountry
1
ALL1
U.S.A1
ALL1
Flagship PioneeringTherapeutic Area
1
ALL1
OncologyStudy Phase
1
ALL1
Discovery PlatformDeal Type
1
ALL1
FinancingProduct Type
1
ALL1
UndisclosedDosage Form
1
ALL1
OralLead Product
1
ALL1
UndisclosedTarget
1
ALL1
UndisclosedLead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery Platform
Sponsor : Flagship Pioneering
Deal Size : $50.0 million
Deal Type : Financing
Flagship’s Abiologics sets sail with $50M for synthetic protein R&D
Details : The proceeds will advance company's platform and develop a diverse pipeline of medicines, Synteins, with an initial focus on oncology and immunology indications.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
July 23, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery Platform
Sponsor : Flagship Pioneering
Deal Size : $50.0 million
Deal Type : Financing